<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Susceptibility to malignant hyperthermia: Evaluation and management</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Susceptibility to malignant hyperthermia: Evaluation and management</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Susceptibility to malignant hyperthermia: Evaluation and management</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Henry Rosenberg, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Harvey K Rosenbaum, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Stephanie B Jones, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Marianna Crowley, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Feb 21, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Malignant hyperthermia (MH) is a complex genetic disorder of skeletal muscle typically manifesting clinically as a hypermetabolic crisis when a susceptible individual receives a halogenated inhalational anesthetic agent or <a class="drug drug_general" data-topicid="9952" href="/d/drug information/9952.html" rel="external">succinylcholine</a> [<a href="#rid1">1-3</a>]. Patients who are susceptible to MH have skeletal muscle receptor abnormalities that allow excessive myoplasmic calcium to accumulate in the presence of the aforementioned anesthetic triggering agents. Very little is known about the specific mechanisms by which anesthetics interact with these abnormal receptors to trigger an MH crisis [<a href="#rid4">4-6</a>].</p><p>Susceptibility to MH (MHS) may arise de novo or be inherited in an autosomal dominant fashion. MHS is suspected in individuals with a history of a clinical event indicative of an acute MH crisis or with a family history of susceptibility. The mainstay of prevention is the identification of these genetically susceptible individuals. Avoidance of anesthetic triggers in MHS patients and prompt administration of <a class="drug drug_general" data-topicid="9322" href="/d/drug information/9322.html" rel="external">dantrolene</a> when an acute event occurs have reduced the mortality associated with MH from historic rates of 70 percent to &lt;10 percent [<a href="#rid7">7-9</a>]. </p><p>This topic will review the genetic basis and testing for MHS and the safe administration of anesthesia to MHS patients. The pathophysiology, clinical manifestations, diagnosis, and management of an acute MH crisis are discussed separately. (See  <a class="medical medical_review" href="/d/html/401.html" rel="external">"Malignant hyperthermia: Diagnosis and management of acute crisis"</a>.)</p><p class="headingAnchor" id="H336378118"><span class="h1">PREVALENCE</span><span class="headingEndMark"> — </span>The prevalence of MHS is difficult to determine. Published rates of MH susceptibility vary widely depending upon the population studied and the method and criteria for diagnosing MHS. A population based study using family cohorts of patients known to be MHS in France estimated MHS at approximately 1:2000 to 1:3000 [<a href="#rid10">10</a>]. Similarly, the prevalence of mutations known to be associated with MH in the ExAC Browser gene database is 1:2750 [<a href="#rid11">11</a>]. However, less than 75 percent of cases of MHS are associated with these known variants [<a href="#rid12">12</a>]. Lack of exposure to MH triggering agents, incomplete penetrance, and variable expressivity lead to a lower incidence of MH episodes than suggested by gene prevalence rates. For example, in an analysis of 370 individuals in 125 European and Canadian family pedigrees with <em>RYR1</em> MH-causative mutations, the likelihood of an individual with an <em>RYR1</em> mutation developing MH during a triggering anesthetic was approximately 40 percent [<a href="#rid13">13</a>]. </p><p class="headingAnchor" id="H5"><span class="h1">MUTATIONS CAUSING SUSCEPTIBILITY TO MALIGNANT HYPERTHERMIA</span><span class="headingEndMark"> — </span>MHS is conferred by mutations of genes associated with proteins controlling levels of cytosolic calcium and, therefore, skeletal muscle contraction [<a href="#rid14">14,15</a>]. The inheritance of MH follows an autosomal dominant pattern in almost all human cases. A few cases, especially those associated with various myopathies, may follow an autosomal recessive inheritance pattern. Genomic sequencing will help clarify the inheritance pattern in families [<a href="#rid16">16</a>]. Genes responsible for coding proteins of the calcium channel in the sarcoplasmic reticulum are most commonly affected: the ryanodine receptor (RYR1) and the closely-associated dihydropyridine (DHP) and SH3 and cysteine-rich domains 3 (STAC3) receptors [<a href="#rid17">17-20</a>]. Mutations in the gene <em>ASPH</em> (Aspartate Beta-Hydroxylase) expressing junction, a sarcoplasmic reticulum protein that interacts with RYR1 and calsequestrin, have been associated with MHS or exertional heat illness (EHI) [<a href="#rid21">21</a>]. </p><p>The likelihood that a susceptible patient will develop MH depends upon the specific type of receptor mutation [<a href="#rid22">22</a>]. Because of incomplete genetic penetrance and variable expressivity, there is great variability in the clinical expression of the syndrome among individuals and between anesthetic episodes in the same individual [<a href="#rid13">13,23</a>]. (See  <a class="medical medical_review" href="/d/html/401.html" rel="external">"Malignant hyperthermia: Diagnosis and management of acute crisis", section on 'Clinical Features'</a>.)</p><p>More than 50 percent of known cases of MH are caused by <em>RYR1</em> mutations; MH causative mutations are not limited to the amino-terminal of the RYR1 receptor on chromosome 19 in regions that encode the hydrophilic, amino-terminal portion of the RYR1 receptor [<a href="#rid6">6,24,25</a>]. Although nearly 700 distinct <em>RYR1</em> variants have been described [<a href="#rid26">26-35</a>], only 48 have been formally shown to be causative [<a href="#rid25">25</a>]; the remainder await confirmatory studies. </p><p>A small number of known MH-related mutations (approximately 1 percent) are caused by a mutation of the gene <em>CACNA1S</em> that encodes for a subunit of the DHP receptor located on chromosome 1 or on the gene encoding for the STAC3 protein on chromosome 12 [<a href="#rid26">26,31-35</a>]. (See  <a class="medical medical_review" href="/d/html/401.html" rel="external">"Malignant hyperthermia: Diagnosis and management of acute crisis", section on 'Pathophysiology'</a>.)</p><p class="headingAnchor" id="H460387700"><span class="h1">MUSCLE DISEASES NEEDING NON-TRIGGERING ANESTHETICS</span><span class="headingEndMark"> — </span>The diagnosis of a muscle disease raises concern that the patient may also have MHS; association with MHS or with rhabdomyolysis depends on the specific diagnosis (<a class="graphic graphic_table graphicRef65645" href="/d/graphic/65645.html" rel="external">table 1</a>). Patients with myopathies caused by <em>RYR1</em> mutations, notably central core myopathy, are assumed to be MHS. Patients with a history of unexpected or recurrent exertional rhabdomyolysis or exertional heat illness (EHI) may also have a higher than normal risk of MHS and should be treated as MHS unless caffeine-halothane contracture testing is negative or testing reveals a non-MH associated mutation that confers susceptibility to exertional rhabdomyolysis/EHI. In addition, patients with severe statin-induced myopathy may be at increased risk for having an <em>RYR1</em> mutation, and should receive non-triggering anesthetics [<a href="#rid36">36</a>]. </p><p>Patients with several other muscle diseases, notably Duchenne and Becker muscular dystrophy, develop rhabdomyolysis and severe hyperkalemia when exposed to <a class="drug drug_general" data-topicid="9952" href="/d/drug information/9952.html" rel="external">succinylcholine</a> and volatile anesthetics; although this is not MH, one should avoid succinylcholine and volatile anesthetics. For patients with other muscle diseases with sporadic case reports of rhabdomyolysis related to these agents, non-triggering anesthetics have been administered as a precaution, although there is no evidence of MHS. (See <a class="local">'Management of anesthesia in malignant hyperthermia-susceptible patients'</a> below and  <a class="medical medical_review" href="/d/html/94576.html" rel="external">"Anesthesia for children with myopathy and for children who undergo muscle biopsy", section on 'Anesthesia-induced rhabdomyolysis and myopathy'</a>.)</p><p class="headingAnchor" id="H130378866"><span class="h2">Myopathies with ryanodine receptor abnormalities</span><span class="headingEndMark"> — </span>Individuals with myopathy who have MH-linked mutations or variants of unknown significance (VUS) in <em>RYR1</em>, <em>CACNA1S</em>, <em>STAC3</em>, or <em>ASPH</em>, should be anesthetized using non-triggering agents. Caffeine-halothane contracture testing to confirm MHS is not necessary. These conditions include:</p><p class="bulletIndent1"><span class="glyph">●</span>Central core myopathy [<a href="#rid31">31,37-40</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Multiminicore disease [<a href="#rid41">41</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>King-Denborough syndrome [<a href="#rid1">1,42</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>STAC3<em> </em>myopathy, in individuals homozygous for <em>STAC3 </em>mutations </p><p></p><p class="bulletIndent1">MH episodes have not been described in heterozygotes [<a href="#rid17">17</a>]. STAC3 myopathy was first described as Native American Myopathy, though it is not limited to Native Americans. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Any other myopathy associated with or caused by an <em>RYR1,</em> <em>STAC3, o</em>r <em>ASPH</em> mutation</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with <em>CACNA1S</em> MH-causal mutations or VUS associated with a personal or family history of MH, rhabdomyolysis, or hyperCK-emia </p><p></p><p class="headingAnchor" id="H130379109"><span class="h2">Exertional rhabdomyolysis</span><span class="headingEndMark"> — </span>Patients with a history of unexpected rhabdomyolysis triggered by either heat or exercise may have a higher incidence of MHS than the general population, based on case reports and small series of MH episodes or MHS (by testing) [<a href="#rid43">43-48</a>]. The possibility of a common etiology is illustrated by a series of six patients with a history of exertional rhabdomyolysis and positive contracture tests, in which five had <em>RYR1</em> mutations [<a href="#rid49">49</a>]. These findings were confirmed in a Canadian cohort of patients with a history of exertional rhabdomyolysis and a subsequent positive MH contracture biopsy and known MH-causative mutations [<a href="#rid50">50</a>]. Because of these findings, some experts, including the authors, advocate treating patients with a history of unexpected heat- or exercise-induced rhabdomyolysis as MHS unless such episodes are proven to be caused by a heritable disorder of muscle metabolism, inflammatory or endocrine disorder. We suggest genetic testing for an MH-causative mutation, and counsel MHS patients they might be at higher than normal risk of exertional heat illness [<a href="#rid51">51-56</a>]. (See <a class="local">'Risk of non-anesthesia-related MH-like episodes'</a> below.)</p><p></p><p class="headingAnchor" id="H148571758"><span class="h2">Severe statin-induced myopathy</span><span class="headingEndMark"> — </span>Severe myopathy is a rare adverse effect of therapy with statin medications. (See  <a class="medical medical_review" href="/d/html/6833.html" rel="external">"Statin muscle-related adverse events"</a>.) </p><p>Patients with severe statin-induced myopathy (ie, incapacitating muscle pain and/or weakness related to statin therapy, often accompanied by rhabdomyolysis and plasma creatine kinase elevation) may be at increased risk for having the <em>RYR1</em> mutation [<a href="#rid57">57-59</a>]. We treat these patients as MHS and suggest genetic testing for the <em>RYR1</em> mutation.</p><p class="headingAnchor" id="H112418375"><span class="h2">Muscle disorders with intraoperative rhabdomyolysis</span><span class="headingEndMark"> — </span>A number of muscle disorders do not appear to confer higher risk of MHS, but are associated with development of hyperkalemia or rhabdomyolysis following administration of <a class="drug drug_general" data-topicid="9952" href="/d/drug information/9952.html" rel="external">succinylcholine</a> or, less often, when volatile anesthetics are used (<a class="graphic graphic_table graphicRef65645" href="/d/graphic/65645.html" rel="external">table 1</a>). </p><p class="headingAnchor" id="H460388010"><span class="h3">Dystrophinopathies</span><span class="headingEndMark"> — </span>Duchenne and Becker muscular dystrophy are both X-linked, recessive disorders that lead to abnormal formation of dystrophin, a muscle-stabilizing protein. They are associated with severe hyperkalemia, leading to cardiac arrest following administration of <a class="drug drug_general" data-topicid="9952" href="/d/drug information/9952.html" rel="external">succinylcholine</a>, and rhabdomyolysis may result from administration of volatile anesthetics [<a href="#rid60">60,61</a>]. While this clinical syndrome may resemble acute MH and is related to abnormal calcium release in the muscle, the etiology is different. Although many patients with dystrophinopathies have received halogenated volatile agents safely, most experts now recommend administration of non-triggering anesthetics to these patients.</p><p class="headingAnchor" id="H460388059"><span class="h3">Enzymopathies of skeletal muscle</span><span class="headingEndMark"> — </span>There are case reports of patients with these diseases who have had positive caffeine-halothane contracture tests (CHCTs), but the interpretation of this test in the setting of a coexisting myopathy is unclear [<a href="#rid61">61</a>]. Due to case reports of rhabdomyolysis, we consider it prudent to avoid <a class="drug drug_general" data-topicid="9952" href="/d/drug information/9952.html" rel="external">succinylcholine</a>. The limited evidence does not support superior safety of total intravenous anesthesia (TIVA) or omitting potent inhalation anesthetics in patients with these conditions:</p><p class="bulletIndent1"><span class="glyph">●</span>Myoadenylate deaminase deficiency [<a href="#rid62">62</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Myophosphorylase deficiency (McArdle disease) [<a href="#rid63">63-65</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Carnitine palmitoyltransferase type 2 deficiency [<a href="#rid66">66,67</a>]</p><p></p><p class="headingAnchor" id="H3337475597"><span class="h4">Brody disease</span><span class="headingEndMark"> — </span>Brody disease is a very rare (1 in 10 million) autosomal recessive myopathy that results in exercise-induced muscle stiffness and cold-induced myalgia and muscle cramps. It is associated with mutations in the <em>ATP2A1</em> gene, which encodes for the sarcoplasmic/endoplasmic reticulum Ca<sup>2+</sup> ATPase type 1 (SERCA1) protein. A report of the clinical characteristics of 40 patients described two that manifested hyperthermia and rhabdomyolysis following general anesthesia with MH triggering agents [<a href="#rid68">68</a>]. Although this was unlikely to represent true MH, it would be prudent to avoid inhalation gases and <a class="drug drug_general" data-topicid="9952" href="/d/drug information/9952.html" rel="external">succinylcholine</a> in these patients. </p><p class="headingAnchor" id="H11"><span class="h1">MUSCLE DISEASES COMPATIBLE WITH MALIGNANT HYPERTHERMIA-TRIGGERING AGENTS</span><span class="headingEndMark"> — </span>A number of other genetic syndromes have historically been associated with MHS, but patients with these syndromes are now thought to be at no greater risk for MH than the general population. </p><p class="bulletIndent1"><span class="glyph">●</span>MH-triggering agents (ie, volatile anesthetics and <a class="drug drug_general" data-topicid="9952" href="/d/drug information/9952.html" rel="external">succinylcholine</a>) are not contraindicated for patients with the following conditions: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Osteogenesis imperfecta [<a href="#rid69">69-72</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Noonan Syndrome [<a href="#rid73">73</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Volatile anesthetics may be used, but <a class="drug drug_general" data-topicid="9952" href="/d/drug information/9952.html" rel="external">succinylcholine</a> should be avoided in patients with the following conditions, which result in myopathy or muscle atrophy, because of potential for life threatening hyperkalemia. The response to nondepolarizing neuromuscular blocking agents may also be unpredictable. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Arthrogryposis multiplex congenita [<a href="#rid74">74-76</a>] (most often due to neurologic disorder rather than primary muscle disease).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Myotonias [<a href="#rid77">77,78</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hypokalemic periodic paralysis (HypoPP) is a rare autosomal dominant disorder that is often due to mutations in <em>CACNA1S</em>; approximately 1 percent of MH patients have mutations in <em>CACNA1S </em>not associated with HypoPP. A theoretical association between MH and HypoPP in this small subset of patients has been made, but never confirmed [<a href="#rid79">79</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Mitochondrial myopathies [<a href="#rid62">62</a>] (see  <a class="medical medical_review" href="/d/html/94576.html" rel="external">"Anesthesia for children with myopathy and for children who undergo muscle biopsy", section on 'Neuromuscular blocking agents'</a> and  <a class="medical medical_review" href="/d/html/94535.html" rel="external">"Clinical use of neuromuscular blocking agents in anesthesia", section on 'Adverse effects of succinylcholine'</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Neuroleptic malignant syndrome (NMS) [<a href="#rid80">80-83</a>], an idiosyncratic response to neuroleptic medications. <a class="drug drug_general" data-topicid="9952" href="/d/drug information/9952.html" rel="external">Succinylcholine</a> should be avoided in patients with NMS with significant rhabdomyolysis.  </p><p></p><p class="headingAnchor" id="H336379131"><span class="h1">IDENTIFICATION OF MALIGNANT HYPERTHERMIA-SUSCEPTIBLE PATIENTS</span><span class="headingEndMark"> — </span>The mainstay of MH prevention is the identification of genetically susceptible individuals. This is primarily done by obtaining a personal and family history of prior adverse reactions to anesthetics and examining these events in detail; there are no practical MHS screening tests. Patients with a suspicious personal or family history are presumed to be MHS for the purpose of planning anesthesia until further evaluated by history, review of medical and anesthetic records, or testing.</p><p class="headingAnchor" id="H11362927"><span class="h2">Anesthetic history</span><span class="headingEndMark"> — </span>The majority of patients with a suspected MH event will deny a history of prior problems related to anesthesia. However, a negative prior history does not exclude MHS. Approximately one-half of patients who develop acute MH have one or two uneventful exposures to triggering agents [<a href="#rid84">84,85</a>], and many patients who develop MH have had multiple previous uneventful anesthetics that included administration of triggering agents [<a href="#rid86">86</a>].</p><p>When a patient reports a personal history or relative with a history of an adverse reaction to anesthesia, the affected patient's anesthesia and hospital records (if available) should be reviewed and assessed for the likelihood of MH (see  <a class="medical medical_review" href="/d/html/401.html" rel="external">"Malignant hyperthermia: Diagnosis and management of acute crisis", section on 'Clinical signs'</a>). If details of a suspicious episode are unavailable, it is prudent to treat the patient as MHS until further evaluated by testing.</p><p>A clinical grading scale has been developed to help determine the likelihood that a prior event represents true MH [<a href="#rid87">87</a>]. The scale assigns points to family history and clinical diagnostic criteria in the categories that define MH events, including rigidity, rhabdomyolysis, fever, tachycardia, respiratory acidosis, and other laboratory abnormalities (<a class="calc calc_professional" href="/d/html/13458.html" rel="external">calculator 1</a>). The MH clinical grading scale was developed by a consensus of experts, and has not been validated by confirmatory genetic or contracture testing. Nonetheless, many experts believe that the scale can be used to counsel patients and make recommendations for testing.</p><p>In the MH grading scale, important clinical indicators that a reported event was likely MH include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Respiratory acidosis – The presence of end-tidal carbon dioxide (ETCO<sub>2</sub>) &gt;55 mmHg or partial pressure of carbon dioxide (PaCO<sub>2</sub>) &gt;60 mmHg with controlled ventilation; ETCO<sub>2</sub> &gt;60 mmHg or PaCO<sub>2</sub> &gt;65 mmHg with spontaneous ventilation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Metabolic acidosis – Base deficit &gt;8 mEq, pH &lt;7.25.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Muscle rigidity – Severe masseter muscle rigidity (MMR) or generalized rigidity that does not abate with non-depolarizing neuromuscular blocking agents.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Muscle breakdown – Serum creatine kinase (CK) &gt;20,000 international units/L following <a class="drug drug_general" data-topicid="9952" href="/d/drug information/9952.html" rel="external">succinylcholine</a> use; &gt;10,000 international units/L without succinylcholine; cola-colored urine in the postoperative period.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Temperature – Rapidly increasing temperature, or core temperature &gt;38.8°C (101.8°F)</p><p></p><p class="headingAnchor" id="H1444338500"><span class="h2">Non-anesthesia-related MH-like episodes</span><span class="headingEndMark"> — </span>MH susceptibility (and <em>RYR1</em> myopathy) should be in the differential diagnosis for patients who exhibit unexplained stress-induced fever, muscle cramping or rigidity, or other characteristics of MH, unrelated to exposure to anesthesia. (See  <a class="medical medical_review" href="/d/html/401.html" rel="external">"Malignant hyperthermia: Diagnosis and management of acute crisis", section on 'Clinical Features'</a>.) Isolated fever (ie, without rhabdomyolysis or exaggerated carbon dioxide production) is not consistent with MH.</p><p>There are a number of case reports of patients who have developed unexplained fevers and/or muscle cramping in response to either hot environments and/or strenuous exercise, or infection, and who were either known to be MHS or were subsequently found to be MHS related to an <em>RYR1</em> MH-causative variant [<a href="#rid51">51-54,88,89</a>]. These events have been referred to as "awake MH" [<a href="#rid51">51</a>], to distinguish them from MH triggered by anesthetics. In most cases, symptoms have abated either spontaneously or after self-administration of oral <a class="drug drug_general" data-topicid="9322" href="/d/drug information/9322.html" rel="external">dantrolene</a>, but several cases have rapidly proceeded to accelerated hyperthermia, hyperkalemia, and death [<a href="#rid51">51,54,90</a>].</p><p>We suggest prescribing as-needed oral <a class="drug drug_general" data-topicid="9322" href="/d/drug information/9322.html" rel="external">dantrolene</a> for MHS patients who have a history of stress-induced MH-like signs and symptoms, as discussed below. Clinicians may consider prophylactic intravenous dantrolene prior to non-triggering anesthesia in this small subset of MHS individuals, as the reported anesthetic experience with these patients is limited and includes case reports of MH despite avoidance of volatile anesthetic agents. (See <a class="local">'Risk of non-anesthesia-related MH-like episodes'</a> below.) </p><p class="headingAnchor" id="H17"><span class="h2">Malignant hyperthermia susceptibility testing</span><span class="headingEndMark"> — </span>Candidates for testing for MHS are those with a past episode likely to have been MH (eg, a clinical grading score of 20 or higher) and family members of MHS patients. The MH testing sequence we follow for patients and family members is shown in an algorithm (<a class="graphic graphic_algorithm graphicRef118417" href="/d/graphic/118417.html" rel="external">algorithm 1</a>). (See <a class="local">'Anesthetic history'</a> above and <a class="local">'Testing for family members'</a> below.)</p><p class="headingAnchor" id="H4155000178"><span class="h3">Testing options</span><span class="headingEndMark"> — </span>The most sensitive test for MHS is the contracture test; it is considered the definitive test to rule out MH. Contracture testing is an in vitro muscle bioassay available only at specialized testing centers, and may not be paid for by insurance [<a href="#rid91">91</a>]. The test is highly sensitive, so negative results generally rule out a diagnosis of MHS [<a href="#rid92">92,93</a>]. However, there is up to a 20 percent false-positive rate. (See <a class="local">'Contracture test'</a> below.)</p><p>Patients with a positive contracture test should undergo genetic testing to look for a causative MH mutation. If one is found, other family members may be tested to look for similar mutations to confirm their MHS status as well. Not all mutations that cause MH have been identified, so absence of an MH-causative mutation does not rule out MH susceptibility. An estimated 14 to 23 percent of MHS families in the United Kingdom do not have an MH causative mutation in <em>RYR1</em>, <em>CACNA1S</em>, or <em>Stac3</em>. Positive genetic tests in patients with negative contracture tests have occurred [<a href="#rid23">23,94</a>]. (See <a class="local">'Genetic tests'</a> below.)</p><p>Despite the possibility of a false-negative result with genetic testing, most patients choose to undergo molecular genetic testing first, as this test requires only a blood sample, thereby avoiding the surgery and cost of contracture testing. </p><p>Other patients prefer to simply consider themselves and their family members MHS without testing. This strategy is practical, but it does not provide guidance or specific answers to the patient or their family members. Furthermore, the patient is then labeled as MHS, with implications for future anesthetics, ineligibility for military service, and possible limitations in occupational and insurance choices.</p><p>It has been suggested that a baseline elevation of CK can be used as a screening tool for MHS, but this has not proven to be sufficiently sensitive nor specific for MHS.</p><p class="headingAnchor" id="H18"><span class="h3">Contracture test</span></p><p class="headingAnchor" id="H11363139"><span class="h4">Indications for contracture testing</span></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with a history suspicious for MH (wait three to six months post event, depending upon the degree of rhabdomyolysis). (See  <a class="medical medical_review" href="/d/html/401.html" rel="external">"Malignant hyperthermia: Diagnosis and management of acute crisis", section on 'Clinical signs'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with MMR during anesthesia with a triggering agent with evidence of rhabdomyolysis (eg, CK over 10,000). (See  <a class="medical medical_review" href="/d/html/401.html" rel="external">"Malignant hyperthermia: Diagnosis and management of acute crisis", section on 'Masseter muscle rigidity'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with a known MHS relative (as determined by positive muscle contracture test or suspicious episode), but without a known MH-causing mutation. (See <a class="local">'Testing for family members'</a> below.)</p><p></p><p>Other clinical scenarios in which contracture testing may be helpful include:</p><p class="bulletIndent1"><span class="glyph">●</span>Unexplained rhabdomyolysis following anesthesia</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Severe or recurrent inexplicable exercise- or heat-induced rhabdomyolysis</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with a suspicious history who are contemplating military service</p><p></p><p class="headingAnchor" id="H20"><span class="h4">Contracture test protocols</span><span class="headingEndMark"> — </span>Contracture tests evaluate the in vitro response of the patient's skeletal muscle (a 3- to 4-inch biopsy from the thigh) to RYR1 agonists (caffeine and halothane). The testing is a bioassay using fresh tissue, so the biopsy must be performed at an MH Muscle Biopsy Center. A list <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.mhaus.org%2Ftesting%2Fmuscle-biopsy-chct%2Fchct-muscle-biopsy-testing-centers%2F&amp;token=kKXHxK%2Bt2cji8cnnyYI7JFa8V2HOukPxHkAwIS4T706v7HrbBHnuyyjiMKjpIH4%2FhGb%2BC%2B%2FOl262RBsMw4hHfm%2F2mH3PVgAevEBdouXmkf4%3D&amp;TOPIC_ID=403" target="_blank">of centers that perform contracture testing and muscle biopsies for MHS</a> can be found on the Malignant Hyperthermia Association of the United States (MHAUS) website. Abnormally high levels of contractile force with agonist exposure indicate MHS. Testing should occur at least three to six months after a suspected MH event, depending upon the degree of rhabdomyolysis.</p><p>Two different protocols were developed independently:</p><p class="bulletIndent1"><span class="glyph">●</span>The caffeine-halothane contracture test (CHCT) by the North American Malignant Hyperthermia Group, with sensitivity 97 percent, specificity 78 percent [<a href="#rid95">95</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The in vitro contracture test (IVCT) by the European Malignant Hyperthermia Group, with sensitivity 99 percent, specificity 94 percent [<a href="#rid96">96</a>].</p><p></p><p>Although these protocols use slightly different methodologies, there are no appreciable differences in test accuracy. The reported differences in sensitivity and specificity are due to the unique methods used, for a test that has no true gold standard for definitive diagnosis. The true rates of false-positives and false-negatives are therefore unknown.</p><p class="headingAnchor" id="H11364888"><span class="h4">Contracture test results</span><span class="headingEndMark"> — </span>A contracture test is considered positive if the patient's muscle demonstrates an exaggerated response to exposure to either halothane or caffeine. Results of the CHCT used in North America are discussed here.</p><p class="bulletIndent1"><span class="glyph">●</span>Negative – There is a low false-negative rate (sensitivity &gt;97 percent), so this generally rules out a diagnosis of MHS [<a href="#rid92">92</a>]. These patients may receive triggering anesthetics. There have been case reports, however, of individuals with known MH mutations and negative contracture test results [<a href="#rid31">31</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Positive – These patients are considered MHS and should not receive triggering anesthetics. Perhaps one in five patients with a positive contracture test has a false-positive result [<a href="#rid92">92</a>]. Despite a relatively high false-positive rate, most MH experts believe that patients with a positive test should be considered MHS because of the potential life-threatening consequences of an MH episode. A positive CHCT result should be followed up with genetic testing to guide further testing for family members. However, some mutations have not been identified, and absence of known pathogenic variants does not change the diagnosis of MHS for the index patient (<a class="graphic graphic_algorithm graphicRef118417" href="/d/graphic/118417.html" rel="external">algorithm 1</a>).</p><p></p><p class="headingAnchor" id="H21"><span class="h3">Genetic tests</span><span class="headingEndMark"> — </span>Molecular genetic testing requires only a blood sample that is sent to a testing center. A list of laboratories that perform testing for MHS can be found at the Malignant Hyperthermia Association of the United States (MHAUS) list of <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.mhaus.org%2Ftesting%2Fgenetic-testing%2Fgenetic-testing-centers%2F&amp;token=kKXHxK%2Bt2cji8cnnyYI7JFa8V2HOukPxHkAwIS4T706na3nCF2hwYkpY7IK4pBpW6FTWRzLL00p2v4qjbRnphw%3D%3D&amp;TOPIC_ID=403" target="_blank">Genetic Testing Centers</a>. Genetic testing laboratories have slightly different approaches to testing for MHS; NextGen sequencing is the standard methodology. </p><p>Typically, a genetic panel evaluates the most common <em>RYR1</em> mutations on chromosome 19 [<a href="#rid23">23,28,97-100</a>] and mutations associated with <em>CACNA1S</em> and <em>STAC3</em> genes. Once a specific MH-causing mutation is discovered, other family members can be tested for only that causative mutation at a reduced price. However, more than one pathogenic variant may exist within a family, and some experts advise that family members who test negative to a proband's known mutation should still undergo contracture testing to definitively rule out MHS [<a href="#rid10">10,101,102</a>]. (See <a class="local">'Genetic test results'</a> below.)</p><p class="headingAnchor" id="H22"><span class="h4">Indications for genetic testing</span><span class="headingEndMark"> — </span>Genetic testing is indicated for:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with a positive contracture test, to determine the presence of an MH-causative mutation</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Individuals with a family member who has a positive contracture or genetic test</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with a clinical history suspicious for MH prior to contracture testing</p><p></p><p class="headingAnchor" id="H447755378"><span class="h4">Genetic test results</span><span class="headingEndMark"> — </span>Results of genetic testing will indicate:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>No DNA variation found –</strong> This does not rule out MHS; these patients should be treated as MHS unless they have negative contracture testing. Since the genetic basis for MHS is incompletely understood, the overall sensitivity of full <em>RYR1</em> panel testing is only about 70 percent [<a href="#rid23">23,35,103</a>]. Whole exome sequencing using next-generation DNA sequencing will detect all known pathogenic variants and is being implemented by genetic testing laboratories. (See  <a class="medical medical_review" href="/d/html/17039.html" rel="external">"Next-generation DNA sequencing (NGS): Principles and clinical applications"</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mutation associated with MH –</strong> These patients are MHS. With a known mutation causing MHS, biologic relatives may have genetic tests rather than contracture tests to determine MHS status. However, if a family member does not have the same mutation as the affected patient, it does not necessarily mean he/she is definitely MH negative [<a href="#rid103">103,104</a>]; such family members should be considered MHS and offered next generation sequencing of <em>RYR1</em>, <em>CACNA1S</em>, and <em>ASPH</em> or contracture testing. Individuals with STAC3 myopathy are homozygous for a <em>STAC3</em> mutation that results in MH-susceptibility. Heterozygotes for <em>STAC3</em> mutations are not myopathic and have not been reported to experience MH episodes.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>DNA variation of uncertain significance (VUS) found in </strong><strong><em>RYR1</em></strong><strong>, </strong><strong><em>CACNA1S</em></strong><strong> or </strong><strong><em>ASPH</em></strong><strong> –</strong> This does not rule out MHS. These patients should be treated as MHS unless they have negative contracture testing.</p><p></p><p class="headingAnchor" id="H23"><span class="h1">COUNSELING</span><span class="headingEndMark"> — </span>When patients have a diagnosis of presumed MHS, we recommend avoidance of triggering anesthetic agents. Anesthesiologists caring for them must be informed that they are MHS. This should continue lifelong, unless definitive testing (contracture testing) is negative. Methods to ensure appropriate treatment of the MHS patient include:</p><p class="bulletIndent1"><span class="glyph">●</span>A letter from the anesthesiologist who supervised the initial incident</p><p class="bulletIndent1"><span class="glyph">●</span>Notation in the patient's personal records and electronic medical record</p><p class="bulletIndent1"><span class="glyph">●</span>Identification bracelets specific for MH (available through the Malignant Hyperthermia Association of the United States [MHAUS] and MedicAlert)</p><p></p><p>We counsel MHS patients and their families to learn as much as possible about the nature of the disorder and direct them to appropriate educational resources. (See <a class="local">'Malignant hyperthermia resources'</a> below.)</p><p class="headingAnchor" id="H4203420385"><span class="h2">Risk of non-anesthesia-related MH-like episodes</span><span class="headingEndMark"> — </span>MHS patients should be questioned about physical stress-induced fever or muscle cramps, and should be cautioned about the possibility of developing heat stroke or MH-like symptoms in hot environments or with exercise. (See <a class="local">'Non-anesthesia-related MH-like episodes'</a> above.) </p><p>In light of continuing reports of MHS individuals who have developed fatal MH-like reactions that were not associated with administration of triggering agents [<a href="#rid51">51-55</a>], we advise MHS individuals to aggressively treat muscle cramping or increases in body temperature as a result of exposure to hot environments, vigorous exercise, or associated with an infectious illness. Unless symptoms are promptly alleviated the patient should seek medical care urgently. </p><p class="bulletIndent1"><span class="glyph">●</span>We suggest early institution of surface cooling or immersion in cold water if available.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We suggest antipyretics (eg, <a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">acetaminophen</a> and/or nonsteroidal antiinflammatory drugs) for fever when there is an infectious or inflammatory component.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For MHS individuals who have a history of non-anesthetic-related fevers, muscle cramping, or rhabdomyolysis, we suggest prescribing oral <a class="drug drug_general" data-topicid="9322" href="/d/drug information/9322.html" rel="external">dantrolene</a> for self-administration if cramping or unexplained fever occur. We recommend 1 to 2 mg/kg oral dantrolene, though the optimal dose of dantrolene in this setting is unknown; in one case report, doses between 1 and 2 mg/kg orally successfully alleviated symptoms of awake MH [<a href="#rid88">88</a>]. It is unknown whether self-administered oral dantrolene can prevent the evolution of these symptoms into a fatal MH-like illness [<a href="#rid51">51,105</a>]. </p><p></p><p>MHS individuals are advised to obtain yearly influenza vaccines, since influenza has been associated with rhabdomyolysis [<a href="#rid106">106</a>] and thus, could be particularly hazardous in MHS individuals.</p><p class="headingAnchor" id="H336379374"><span class="h2">Testing for family members</span><span class="headingEndMark"> — </span>Because MHS has an autosomal-dominant inheritance, first-degree relatives (parents, siblings, and children) have up to a 50 percent chance of MHS and should consider testing (<a class="graphic graphic_algorithm graphicRef118417" href="/d/graphic/118417.html" rel="external">algorithm 1</a>). Other biologic relatives (eg, cousins) may consider testing as well. If the proband has survived the MH episode, we recommend that he/she undergo molecular genetic testing. We would then recommend evaluating the patient's parents to identify the side of the family (maternal or paternal) carrying the mutation; absent consanguinity, this eliminates the need to test the unaffected side of the family if only one mutation has been identified. If the proband does not have an MH-causative mutation, caffeine-halothane contracture testing may be offered to both parents. If both parents are negative for MHS by contracture testing, suggesting a spontaneous mutation, the risk to family members other than the patient's children is low.</p><p class="headingAnchor" id="H24"><span class="h1">MANAGEMENT OF ANESTHESIA IN MALIGNANT HYPERTHERMIA-SUSCEPTIBLE PATIENTS</span><span class="headingEndMark"> — </span>MHS patients can be safely anesthetized using non-triggering agents. End-tidal carbon dioxide (ETCO<sub>2</sub>) levels, minute ventilation, and core body temperature are monitored closely in MHS patients.</p><p class="headingAnchor" id="H2126295"><span class="h2">Equipment preparation</span><span class="headingEndMark"> — </span>The anesthesia machine should be "cleaned" of traces of volatile anesthetics. The Malignant Hyperthermia Association of the United States (MHAUS) recommends using activated charcoal filters if available (<a class="graphic graphic_picture graphicRef81599" href="/d/graphic/81599.html" rel="external">picture 1</a>). Flush with high fresh gas flows (≥10 L/min) for 90 seconds prior to placing the activated charcoal filters on <strong>both</strong> the inspiratory and expiratory ports. These filters are effective in keeping gas concentration below 5 ppm for up to 12 hours with fresh gas flows of at least 3 L/min [<a href="#rid107">107,108</a>].</p><p>If activated charcoal filters are not available, MHAUS recommends flushing with high-flow (at least 10 L per minute) oxygen, with an unused breathing bag attached to the Y-piece of the circle system and the ventilator set to inflate the bag periodically. Due to variability in anesthesia machines, the manufacturer's guidelines regarding duration should be followed [<a href="#rid109">109</a>]. Some anesthesia machines require flushing for more than two hours to achieve residual volatile anesthetic concentrations lower than 5 ppm. If activated charcoal filters are not used, high-flows should be continued throughout the case, as plastic and rubber components of the anesthesia machine may emit previously absorbed volatile agents [<a href="#rid110">110-112</a>].  </p><p>Anesthetic vaporizers should be removed or taped over with dial in “OFF” position to avoid accidental administration of volatile anesthetic. New or disposable breathing circuits should be used. Some experts, including MHAUS, recommend changing the carbon dioxide (CO<sub>2</sub>) absorbent [<a href="#rid109">109</a>].</p><p>The MH treatment cart should be readily available with supplies and medications needed to treat an acute MH episode (<a class="graphic graphic_table graphicRef67323" href="/d/graphic/67323.html" rel="external">table 2</a>).</p><p class="headingAnchor" id="H26"><span class="h2">Safe anesthetic agents</span><span class="headingEndMark"> — </span>General anesthesia, regional anesthesia (neuraxial anesthesia or nerve blocks), or monitored anesthesia care are all options for these patients if triggering agents are avoided. Other patient- and situation-specific factors should be considered in choosing the type of anesthesia. In a large population-based study of approximately 958,000 patients who underwent general anesthesia in Canada, 2900 patients who were known or strongly suspected to be MH susceptible and received a non-triggering anesthetic had no higher risk of adverse postoperative outcomes (ie, death, readmission to hospital, or major postoperative complication, within 30 days of surgery) than patients who were not MH susceptible [<a href="#rid113">113</a>]. </p><p>MH-triggering agents are the volatile anesthetics (eg, <a class="drug drug_general" data-topicid="9887" href="/d/drug information/9887.html" rel="external">sevoflurane</a>, <a class="drug drug_general" data-topicid="8891" href="/d/drug information/8891.html" rel="external">desflurane</a>, <a class="drug drug_general" data-topicid="8992" href="/d/drug information/8992.html" rel="external">isoflurane</a>, halothane) and <a class="drug drug_general" data-topicid="9952" href="/d/drug information/9952.html" rel="external">succinylcholine</a>; all other medications are safe [<a href="#rid15">15</a>].</p><p>"Non-triggering" agents that can be safely administered to MHS patients include:</p><p class="bulletIndent1"><span class="glyph">●</span>All intravenous anesthetic and sedative agents, including <a class="drug drug_general" data-topicid="9826" href="/d/drug information/9826.html" rel="external">propofol</a>, <a class="drug drug_general" data-topicid="8588" href="/d/drug information/8588.html" rel="external">ketamine</a>, <a class="drug drug_general" data-topicid="8428" href="/d/drug information/8428.html" rel="external">etomidate</a>, <a class="drug drug_general" data-topicid="8897" href="/d/drug information/8897.html" rel="external">dexmedetomidine</a>, and barbiturates</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>All local anesthetics (eg, <a class="drug drug_general" data-topicid="9558" href="/d/drug information/9558.html" rel="external">lidocaine</a>, <a class="drug drug_general" data-topicid="9169" href="/d/drug information/9169.html" rel="external">bupivacaine</a>, <a class="drug drug_general" data-topicid="9873" href="/d/drug information/9873.html" rel="external">ropivacaine</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Nondepolarizing neuromuscular blocking agents (eg, <a class="drug drug_general" data-topicid="10041" href="/d/drug information/10041.html" rel="external">vecuronium</a>, <a class="drug drug_general" data-topicid="9872" href="/d/drug information/9872.html" rel="external">rocuronium</a>, <a class="drug drug_general" data-topicid="9270" href="/d/drug information/9270.html" rel="external">cisatracurium</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pain relievers and anxiolytics, including opioids and benzodiazepines</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Antiemetics</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Inhalational agents limited to <a class="drug drug_general" data-topicid="10086" href="/d/drug information/10086.html" rel="external">nitrous oxide</a> and xenon</p><p></p><p>Administration of perioperative <a class="drug drug_general" data-topicid="9322" href="/d/drug information/9322.html" rel="external">dantrolene</a> for prophylaxis is not necessary [<a href="#rid114">114</a>].</p><p class="headingAnchor" id="H27"><span class="h2">Ambulatory surgery</span><span class="headingEndMark"> — </span>Routine day surgery discharge criteria are applicable to MHS patients who have not received anesthetic triggering agents and otherwise do well during and following their surgery [<a href="#rid115">115</a>]. A prospective study of 125 MHS patients who received non-triggering anesthetics reported no evidence of MH-related problems when standard post-anesthesia care unit discharge criteria were followed [<a href="#rid116">116</a>]. In the previously mentioned retrospective Canadian database study, MH susceptibility in patients who had ambulatory surgery was not associated with an increase in major adverse postoperative events, but was associated with an increase in postoperative emergency department visits within 90 days [<a href="#rid113">113</a>]. </p><p>Upon discharge, the patient should be instructed to call their clinician or go to the emergency department if elevated temperature or brown urine develops.</p><p class="headingAnchor" id="H537492361"><span class="h2">Susceptibility to malignant hyperthermia in pregnancy</span><span class="headingEndMark"> — </span>A pregnant MHS patient may safely receive neuraxial anesthesia or analgesia; if general anesthesia is required, non-triggering anesthetic agents should be administered.</p><p>If the partner of a parturient is MHS, the fetus may be MHS. Although there are no cases reported of a fetus developing an MH crisis from in utero exposure to triggering agents, MHAUS recommends using a non-triggering technique if a pregnant woman carrying a potentially susceptible fetus requires general anesthesia [<a href="#rid117">117</a>].</p><p class="headingAnchor" id="H28"><span class="h1">MALIGNANT HYPERTHERMIA RESOURCES</span></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.mhaus.org%2F&amp;token=kKXHxK%2Bt2cji8cnnyYI7JGRDR9nZPP1yEgngiNnrOmo%3D&amp;TOPIC_ID=403" target="_blank">Malignant Hyperthermia Association of the United States</a> (MHAUS) – MHAUS was formed in 1981 to educate the medical community and the public about MH and serve as a resource for affected families. A wide variety of educational information for health professionals and the public is available at their internet site.</p><p></p><p class="bulletIndent1">MHAUS maintains a free, 24-hour "hotline" for acute cases (1-800-MH HYPER) that is continuously staffed by anesthesiologists who are experts in managing cases of MH, answering questions about prospective management of MHS patients, and directing callers to appropriate resources.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fanest.ufl.edu%2Fnamhr%2F&amp;token=5xBb6k%2FhzSZyD97HOJvQfcTOik9k9LfqVgEUlpJEYEPQpaDaIMAy39lEp0d0xQPR&amp;TOPIC_ID=403" target="_blank">North American MH Registry</a> was established to collect and analyze information about clinical episodes of MH and the results of laboratory tests.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.emhg.org%2F&amp;token=NyRkA1K%2BEfcjom0B%2BqrukrHwNpJGDSxJQUYhYGfFxw0%3D&amp;TOPIC_ID=403" target="_blank">European Malignant Hyperthermia Group</a> provides information on European protocols.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.leedsth.nhs.uk%2Fa-z-of-services%2Fmalignant-hyperthermia%2F&amp;token=D7wnjJm3OrkcMmW%2FMpWX3Krn11pwlW8xvkJT%2FawfS9Nujp9%2Bldp7MYcel46E5P8FScgcaTSwtJ37BoLneyTMuItiXow7E12Judo36w6Hkl4%3D&amp;TOPIC_ID=403" target="_blank">Malignant Hyperthermia Unit at St. James Hospital, UK, British Malignant Hyperthermia Association</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fmalignanthyperthermia.org.au%2Fresource-kit%2F&amp;token=Q16ezfbXNfIG7du7kPbffS3SazLCWAYhOE9z5yOfsbRyrmKl3TBEyz8lu4xEwpLK0nikM92%2FeRkhJ%2Bn5kEC4Ig%3D%3D&amp;TOPIC_ID=403" target="_blank">Malignant Hyperthermia Australia and New Zealand</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Japanese Malignant Hyperthermia Association – 4<sup>th</sup> Nishi Tenma Park Bldg, 3-13-9 Nishi Tenma, Kita-ku, Osaka-shi, 530-0047, Japan. C/O COML (Consumer Organization for Medicine &amp; Law). Japanese Malignant Hyperthermia Association membership and inquiry counter (telephone/fax: 06-6361-3446; email: <a class="__cf_email__" data-cfemail="7a3037323b484248433a12150e171b131654191517" href="/cdn-cgi/l/email-protection">[email protected]</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.ryr1.org%2F&amp;token=bU%2BtezdjDSYUG7yya6kBpig6jIl%2FjDPYQq4hjDHMoaU%3D&amp;TOPIC_ID=403" target="_blank">The RYR1 Foundation</a>.</p><p></p><p class="headingAnchor" id="H2740350879"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/122055.html" rel="external">"Society guideline links: Malignant hyperthermia"</a>.)</p><p class="headingAnchor" id="H29"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genetics of malignant hyperthermia (MH)</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Susceptibility to malignant hyperthermia (MHS) is a genetic disorder of skeletal muscle calcium regulation that can manifest clinically as a hypermetabolic crisis (malignant hyperthermia [MH] crisis) in genetically-susceptible individuals exposed to volatile anesthetics or <a class="drug drug_general" data-topicid="9952" href="/d/drug information/9952.html" rel="external">succinylcholine</a>. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>MHS individuals have skeletal muscle receptor abnormalities, allowing excessive intracellular calcium to accumulate in response to volatile anesthetics or <a class="drug drug_general" data-topicid="9952" href="/d/drug information/9952.html" rel="external">succinylcholine</a>; this triggers intracellular events, leading to skeletal muscle hypermetabolism. MHS is caused by mutations in genes that are responsible for coding calcium channel proteins and receptors (RYR1, DHP, ASPH and STAC3). (See <a class="local">'Mutations causing susceptibility to malignant hyperthermia'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>MHS is usually inherited in an autosomal-dominant fashion. Its prevalence is unknown but is estimated at 1:1500. Due to variable penetrance, not all exposures of MHS patients to triggering agents result in MH crisis. (See <a class="local">'Prevalence'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with some muscle diseases have genetic abnormalities in <em>RYR1</em>, <em>CACNA1S</em>, <em>ASPH</em> or <em>STAC3</em> genes that confer MHS; these include central core myopathy (and all other ryanodinopathies), Native American myopathy, and King-Denborough syndrome (<a class="graphic graphic_table graphicRef65645" href="/d/graphic/65645.html" rel="external">table 1</a>). (See <a class="local">'Myopathies with ryanodine receptor abnormalities'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Identifying MH susceptibility – </strong>The mainstay of prevention of MH is the identification of MHS individuals. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>MHS is suspected in patients with a prior likely MH event and is confirmed by susceptibility testing. A clinical grading scale for possible MH events assists in determining whether past events were actually MH. (See <a class="local">'Identification of malignant hyperthermia-susceptible patients'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with a history of exercise- or heat-induced rhabdomyolysis or with severe statin-induced myopathy may have a higher incidence of MHS than the general population. For patients with heat or exercise induced rhabdomyolysis we suggest testing for MHS (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). We also suggest testing for MHS for patients with severe statin induced myopathy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). We assume that these patients are MHS unless they have tested negative. (See <a class="local">'Exertional rhabdomyolysis'</a> above and <a class="local">'Severe statin-induced myopathy'</a> above.)</p><p></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Myopathies associated with rhabdomyolysis</strong> – Some myopathic conditions are associated with increased risk for life-threatening rhabdomyolysis or hyperkalemia after receiving a volatile anesthetic or <a class="drug drug_general" data-topicid="9952" href="/d/drug information/9952.html" rel="external">succinylcholine</a>. This clinical syndrome may resemble, but is not, acute MH. Associated conditions include the dystrophinopathies, myoadenylate deaminase deficiency, McArdle disease, and carnitine palmitoyltransferase type 2 deficiency (<a class="graphic graphic_table graphicRef65645" href="/d/graphic/65645.html" rel="external">table 1</a>). Patients with dystrophinopathies are not MHS, but the MH-triggering agents should probably be avoided. (See <a class="local">'Muscle disorders with intraoperative rhabdomyolysis'</a> above.) </p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9952" href="/d/drug information/9952.html" rel="external">Succinylcholine</a> should be avoided in patients with disorders of muscle metabolism or myopathy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>MH testing</strong> – There are no practical MHS screening tests for the general population. Testing for MHS is indicated only in a patient with an event suspicious for MH or in family members of a patient with positive tests (<a class="graphic graphic_algorithm graphicRef118417" href="/d/graphic/118417.html" rel="external">algorithm 1</a>). (See <a class="local">'Identification of malignant hyperthermia-susceptible patients'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Contracture testing is the definitive test for individuals with an event suspicious for MH. It requires a surgical muscle biopsy and is offered at only a limited number of centers. Contracture testing has few false negatives; a negative test effectively rules out MHS. The caffeine-halothane contracture test (used in North America) has about a 20 percent false-positive rate; positive results should be followed up with genetic testing. (See <a class="local">'Contracture test'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Genetic testing is indicated in individuals with a positive contracture test, positive family history for a gene mutation, and those who are unable or unwilling to undergo contracture testing. Genetic testing identifies 60 to 75 percent of MHS individuals. (See <a class="local">'Genetic tests'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Anesthetic management for patients who are MHS</strong> – These patients may safely have general anesthesia, administered without triggering agents (volatile anesthetic gases and <a class="drug drug_general" data-topicid="9952" href="/d/drug information/9952.html" rel="external">succinylcholine</a>). Anesthesia machines should be cleaned of trace potent anesthetic gases, and an MH cart with supplies and medications to manage acute MH (including <a class="drug drug_general" data-topicid="9322" href="/d/drug information/9322.html" rel="external">dantrolene</a>) should be available prior to anesthesia. (See <a class="local">'Management of anesthesia in malignant hyperthermia-susceptible patients'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Non-anesthesia-related MH like episodes – </strong>Some MHS individuals have developed non-anesthetic-related MH-like episodes, triggered by exposure to hot environments and/or strenuous exercise or infection, some of which were associated with fatal hyperkalemia and hyperthermia. For MHS patients with such episodes:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We suggest surface cooling or immersion in cool or cold water for hyperthermia (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). </p><p class="bulletIndent2"><span class="glyph">•</span>We suggest early administration of antipyretics (eg, <a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">acetaminophen</a> or nonsteroidal antiinflammatory drugs) for fever due to inflammation or infection (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). </p><p class="bulletIndent2"><span class="glyph">•</span>For MHS patients who have a history of non-anesthetic-related fevers, muscle cramping, or rhabdomyolysis, we suggest prescribing oral <a class="drug drug_general" data-topicid="9322" href="/d/drug information/9322.html" rel="external">dantrolene</a> for self-administration if unexplained fever or muscle cramps occur (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). If symptoms do not resolve, urgent medical care should be sought.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>MH resources</strong> – Information and resources are available from the Malignant Hyperthermia Association of the United States (MHAUS) and the European Malignant Hyperthermia Group. MHAUS maintains a free, 24-hour "hotline," for assistance in MH emergencies (1-800-MH HYPER). (See <a class="local">'Malignant hyperthermia resources'</a> above.)</p><p></p><p class="headingAnchor" id="H3795007672"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Ronald S Litman, DO, ML (deceased), who contributed as an author to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Denborough M. Malignant hyperthermia. Lancet 1998; 352:1131.</a></li><li><a class="nounderline abstract_t">Simon HB. Hyperthermia. N Engl J Med 1993; 329:483.</a></li><li><a class="nounderline abstract_t">Litman RS, Rosenberg H. Malignant hyperthermia-associated diseases: state of the art uncertainty. Anesth Analg 2009; 109:1004.</a></li><li><a class="nounderline abstract_t">Wappler F. Malignant hyperthermia. Eur J Anaesthesiol 2001; 18:632.</a></li><li><a class="nounderline abstract_t">MacLennan DH, Phillips MS. Malignant hyperthermia. Science 1992; 256:789.</a></li><li><a class="nounderline abstract_t">Lee-Chiong TL Jr, Stitt JT. Disorders of temperature regulation. Compr Ther 1995; 21:697.</a></li><li><a class="nounderline abstract_t">Larach MG, Brandom BW, Allen GC, et al. Cardiac arrests and deaths associated with malignant hyperthermia in north america from 1987 to 2006: a report from the north american malignant hyperthermia registry of the malignant hyperthermia association of the United States. Anesthesiology 2008; 108:603.</a></li><li><a class="nounderline abstract_t">Rosero EB, Adesanya AO, Timaran CH, Joshi GP. Trends and outcomes of malignant hyperthermia in the United States, 2000 to 2005. Anesthesiology 2009; 110:89.</a></li><li><a class="nounderline abstract_t">Larach MG, Brandom BW, Allen GC, et al. Malignant hyperthermia deaths related to inadequate temperature monitoring, 2007-2012: a report from the North American malignant hyperthermia registry of the malignant hyperthermia association of the United States. Anesth Analg 2014; 119:1359.</a></li><li><a class="nounderline abstract_t">Monnier N, Krivosic-Horber R, Payen JF, et al. Presence of two different genetic traits in malignant hyperthermia families: implication for genetic analysis, diagnosis, and incidence of malignant hyperthermia susceptibility. Anesthesiology 2002; 97:1067.</a></li><li class="breakAll">http://exac.broadinstitute.org/gene/ENSG00000196218.</li><li><a class="nounderline abstract_t">Klingler W, Heiderich S, Girard T, et al. Functional and genetic characterization of clinical malignant hyperthermia crises: a multi-centre study. Orphanet J Rare Dis 2014; 9:8.</a></li><li><a class="nounderline abstract_t">Ibarra Moreno CA, Hu S, Kraeva N, et al. An Assessment of Penetrance and Clinical Expression of Malignant Hyperthermia in Individuals Carrying Diagnostic Ryanodine Receptor 1 Gene Mutations. Anesthesiology 2019; 131:983.</a></li><li><a class="nounderline abstract_t">Davis PJ, Brandom BW. The association of malignant hyperthermia and unusual disease: when you're hot you're hot or maybe not. Anesth Analg 2009; 109:1001.</a></li><li><a class="nounderline abstract_t">Gonsalves SG, Dirksen RT, Sangkuhl K, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for the Use of Potent Volatile Anesthetic Agents and Succinylcholine in the Context of RYR1 or CACNA1S Genotypes. Clin Pharmacol Ther 2019; 105:1338.</a></li><li><a class="nounderline abstract_t">Biesecker LG, Dirksen RT, Girard T, et al. Genomic Screening for Malignant Hyperthermia Susceptibility. Anesthesiology 2020; 133:1277.</a></li><li><a class="nounderline abstract_t">Stamm DS, Aylsworth AS, Stajich JM, et al. Native American myopathy: congenital myopathy with cleft palate, skeletal anomalies, and susceptibility to malignant hyperthermia. Am J Med Genet A 2008; 146A:1832.</a></li><li><a class="nounderline abstract_t">Zaharieva I, Sarkozy A, Manzur A, et al. STAC3 p.Trp284Ser associated with congenital myopathy with distinctive dysmorphic features and malignant hyperthermia. Neuromuscul Disord 2017; 27:S39.</a></li><li><a class="nounderline abstract_t">Stamm DS, Powell CM, Stajich JM, et al. Novel congenital myopathy locus identified in Native American Indians at 12q13.13-14.1. Neurology 2008; 71:1764.</a></li><li><a class="nounderline abstract_t">Bailey AG, Bloch EC. Malignant hyperthermia in a three-month-old American Indian infant. Anesth Analg 1987; 66:1043.</a></li><li><a class="nounderline abstract_t">Endo Y, Groom L, Celik A, et al. Variants in ASPH cause exertional heat illness and are associated with malignant hyperthermia susceptibility. Nat Commun 2022; 13:3403.</a></li><li><a class="nounderline abstract_t">Carpenter D, Robinson RL, Quinnell RJ, et al. Genetic variation in RYR1 and malignant hyperthermia phenotypes. Br J Anaesth 2009; 103:538.</a></li><li><a class="nounderline abstract_t">Robinson RL, Anetseder MJ, Brancadoro V, et al. Recent advances in the diagnosis of malignant hyperthermia susceptibility: how confident can we be of genetic testing? Eur J Hum Genet 2003; 11:342.</a></li><li><a class="nounderline abstract_t">Sambuughin N, Holley H, Muldoon S, et al. Screening of the entire ryanodine receptor type 1 coding region for sequence variants associated with malignant hyperthermia susceptibility in the north american population. Anesthesiology 2005; 102:515.</a></li><li class="breakAll">https://www.emhg.org/diagnostic-mutations (Accessed on March 21, 2018).</li><li><a class="nounderline abstract_t">Stewart SL, Hogan K, Rosenberg H, Fletcher JE. Identification of the Arg1086His mutation in the alpha subunit of the voltage-dependent calcium channel (CACNA1S) in a North American family with malignant hyperthermia. Clin Genet 2001; 59:178.</a></li><li><a class="nounderline abstract_t">MacLennan DH, Duff C, Zorzato F, et al. Ryanodine receptor gene is a candidate for predisposition to malignant hyperthermia. Nature 1990; 343:559.</a></li><li><a class="nounderline abstract_t">McCarthy TV, Healy JM, Heffron JJ, et al. Localization of the malignant hyperthermia susceptibility locus to human chromosome 19q12-13.2. Nature 1990; 343:562.</a></li><li><a class="nounderline abstract_t">Yang T, Ta TA, Pessah IN, Allen PD. Functional defects in six ryanodine receptor isoform-1 (RyR1) mutations associated with malignant hyperthermia and their impact on skeletal excitation-contraction coupling. J Biol Chem 2003; 278:25722.</a></li><li><a class="nounderline abstract_t">Broman M, Gehrig A, Islander G, et al. Mutation screening of the RYR1-cDNA from peripheral B-lymphocytes in 15 Swedish malignant hyperthermia index cases. Br J Anaesth 2009; 102:642.</a></li><li><a class="nounderline abstract_t">Brandt A, Schleithoff L, Jurkat-Rott K, et al. Screening of the ryanodine receptor gene in 105 malignant hyperthermia families: novel mutations and concordance with the in vitro contracture test. Hum Mol Genet 1999; 8:2055.</a></li><li><a class="nounderline abstract_t">Girard T, Urwyler A, Censier K, et al. Genotype-phenotype comparison of the Swiss malignant hyperthermia population. Hum Mutat 2001; 18:357.</a></li><li><a class="nounderline abstract_t">Monnier N, Procaccio V, Stieglitz P, Lunardi J. Malignant-hyperthermia susceptibility is associated with a mutation of the alpha 1-subunit of the human dihydropyridine-sensitive L-type voltage-dependent calcium-channel receptor in skeletal muscle. Am J Hum Genet 1997; 60:1316.</a></li><li><a class="nounderline abstract_t">Rueffert H, Olthoff D, Deutrich C, et al. Mutation screening in the ryanodine receptor 1 gene (RYR1) in patients susceptible to malignant hyperthermia who show definite IVCT results: identification of three novel mutations. Acta Anaesthesiol Scand 2002; 46:692.</a></li><li><a class="nounderline abstract_t">Sei Y, Sambuughin NN, Davis EJ, et al. Malignant hyperthermia in North America: genetic screening of the three hot spots in the type I ryanodine receptor gene. Anesthesiology 2004; 101:824.</a></li><li><a class="nounderline abstract_t">Isackson PJ, Wang J, Zia M, et al. RYR1 and CACNA1S genetic variants identified with statin-associated muscle symptoms. Pharmacogenomics 2018; 19:1235.</a></li><li><a class="nounderline abstract_t">Quane KA, Healy JM, Keating KE, et al. Mutations in the ryanodine receptor gene in central core disease and malignant hyperthermia. Nat Genet 1993; 5:51.</a></li><li><a class="nounderline abstract_t">Sewry CA, Müller C, Davis M, et al. The spectrum of pathology in central core disease. Neuromuscul Disord 2002; 12:930.</a></li><li><a class="nounderline abstract_t">Klingler W, Rueffert H, Lehmann-Horn F, et al. Core myopathies and risk of malignant hyperthermia. Anesth Analg 2009; 109:1167.</a></li><li><a class="nounderline abstract_t">Zhang Y, Chen HS, Khanna VK, et al. A mutation in the human ryanodine receptor gene associated with central core disease. Nat Genet 1993; 5:46.</a></li><li><a class="nounderline abstract_t">Guis S, Figarella-Branger D, Monnier N, et al. Multiminicore disease in a family susceptible to malignant hyperthermia: histology, in vitro contracture tests, and genetic characterization. Arch Neurol 2004; 61:106.</a></li><li><a class="nounderline abstract_t">D'Arcy CE, Bjorksten A, Yiu EM, et al. King-denborough syndrome caused by a novel mutation in the ryanodine receptor gene. Neurology 2008; 71:776.</a></li><li><a class="nounderline abstract_t">Tobin JR, Jason DR, Challa VR, et al. Malignant hyperthermia and apparent heat stroke. JAMA 2001; 286:168.</a></li><li><a class="nounderline abstract_t">Figarella-Branger D, Kozak-Ribbens G, Rodet L, et al. Pathological findings in 165 patients explored for malignant hyperthermia susceptibility. Neuromuscul Disord 1993; 3:553.</a></li><li><a class="nounderline abstract_t">Bendahan D, Kozak-Ribbens G, Confort-Gouny S, et al. A noninvasive investigation of muscle energetics supports similarities between exertional heat stroke and malignant hyperthermia. Anesth Analg 2001; 93:683.</a></li><li><a class="nounderline abstract_t">Ryan JF, Tedeschi LG. Sudden unexplained death in a patient with a family history of malignant hyperthermia. J Clin Anesth 1997; 9:66.</a></li><li><a class="nounderline abstract_t">Köchling A, Wappler F, Winkler G, Schulte am Esch JS. Rhabdomyolysis following severe physical exercise in a patient with predisposition to malignant hyperthermia. Anaesth Intensive Care 1998; 26:315.</a></li><li><a class="nounderline abstract_t">Wappler F, Fiege M, Steinfath M, et al. Evidence for susceptibility to malignant hyperthermia in patients with exercise-induced rhabdomyolysis. Anesthesiology 2001; 94:95.</a></li><li><a class="nounderline abstract_t">Sambuughin N, Capacchione J, Blokhin A, et al. The ryanodine receptor type 1 gene variants in African American men with exertional rhabdomyolysis and malignant hyperthermia susceptibility. Clin Genet 2009; 76:564.</a></li><li><a class="nounderline abstract_t">Kraeva N, Sapa A, Dowling JJ, Riazi S. Malignant hyperthermia susceptibility in patients with exertional rhabdomyolysis: a retrospective cohort study and updated systematic review. Can J Anaesth 2017; 64:736.</a></li><li><a class="nounderline abstract_t">Zvaritch E, Gillies R, Kraeva N, et al. Fatal awake malignant hyperthermia episodes in a family with malignant hyperthermia susceptibility: a case series. Can J Anaesth 2019; 66:540.</a></li><li><a class="nounderline abstract_t">Lavezzi WA, Capacchione JF, Muldoon SM, et al. Case report: Death in the emergency department: an unrecognized awake malignant hyperthermia-like reaction in a six-year-old. Anesth Analg 2013; 116:420.</a></li><li><a class="nounderline abstract_t">Potts LE, Longwell JJ, Bedocs P, et al. Improving awareness of nonanesthesia-related malignant hyperthermia presentations: a tale of two brothers. A A Case Rep 2014; 3:23.</a></li><li><a class="nounderline abstract_t">Groom L, Muldoon SM, Tang ZZ, et al. Identical de novo mutation in the type 1 ryanodine receptor gene associated with fatal, stress-induced malignant hyperthermia in two unrelated families. Anesthesiology 2011; 115:938.</a></li><li><a class="nounderline abstract_t">Molenaar JP, Voermans NC, van Hoeve BJ, et al. Fever-induced recurrent rhabdomyolysis due to a novel mutation in the ryanodine receptor type 1 gene. Intern Med J 2014; 44:819.</a></li><li><a class="nounderline abstract_t">Gardner L, Miller DM, Daly C, et al. Investigating the genetic susceptibility to exertional heat illness. J Med Genet 2020; 57:531.</a></li><li><a class="nounderline abstract_t">Vladutiu GD, Isackson PJ, Kaufman K, et al. Genetic risk for malignant hyperthermia in non-anesthesia-induced myopathies. Mol Genet Metab 2011; 104:167.</a></li><li><a class="nounderline abstract_t">Krivosic-Horber R, Dépret T, Wagner JM, Maurage CA. Malignant hyperthermia susceptibility revealed by increased serum creatine kinase concentrations during statin treatment. Eur J Anaesthesiol 2004; 21:572.</a></li><li><a class="nounderline abstract_t">Guis S, Bendahan D, Kozak-Ribbens G, et al. Rhabdomyolysis and myalgia associated with anticholesterolemic treatment as potential signs of malignant hyperthermia susceptibility. Arthritis Rheum 2003; 49:237.</a></li><li><a class="nounderline abstract_t">Gurnaney H, Brown A, Litman RS. Malignant hyperthermia and muscular dystrophies. Anesth Analg 2009; 109:1043.</a></li><li><a class="nounderline abstract_t">Benca J, Hogan K. Malignant hyperthermia, coexisting disorders, and enzymopathies: risks and management options. Anesth Analg 2009; 109:1049.</a></li><li><a class="nounderline abstract_t">Fricker RM, Raffelsberger T, Rauch-Shorny S, et al. Positive malignant hyperthermia susceptibility in vitro test in a patient with mitochondrial myopathy and myoadenylate deaminase deficiency. Anesthesiology 2002; 97:1635.</a></li><li><a class="nounderline abstract_t">Isaacs H, Badenhorst ME, Du Sautoy C. Myophosphorylase B deficiency and malignant hyperthermia. Muscle Nerve 1989; 12:203.</a></li><li><a class="nounderline abstract_t">Lobato EB, Janelle GM, Urdaneta F, Malias MA. Noncardiogenic pulmonary edema and rhabdomyolsis after protamine administration in a patient with unrecognized McArdle's disease. Anesthesiology 1999; 91:303.</a></li><li><a class="nounderline abstract_t">Bollig G, Mohr S, Raeder J. McArdle's disease and anaesthesia: case reports. Review of potential problems and association with malignant hyperthermia. Acta Anaesthesiol Scand 2005; 49:1077.</a></li><li><a class="nounderline abstract_t">Katsuya H, Misumi M, Ohtani Y, Miike T. Postanesthetic acute renal failure due to carnitine palmityl transferase deficiency. Anesthesiology 1988; 68:945.</a></li><li><a class="nounderline abstract_t">Hogan KJ, Vladutiu GD. Malignant hyperthermia-like syndrome and carnitine palmitoyltransferase II deficiency with heterozygous R503C mutation. Anesth Analg 2009; 109:1070.</a></li><li><a class="nounderline abstract_t">Molenaar JP, Verhoeven JI, Rodenburg RJ, et al. Clinical, morphological and genetic characterization of Brody disease: an international study of 40 patients. Brain 2020; 143:452.</a></li><li><a class="nounderline abstract_t">Ryan CA, Al-Ghamdi AS, Gayle M, Finer NN. Osteogenesis imperfecta and hyperthermia. Anesth Analg 1989; 68:811.</a></li><li><a class="nounderline abstract_t">Rampton AJ, Kelly DA, Shanahan EC, Ingram GS. Occurrence of malignant hyperpyrexia in a patient with osteogenesis imperfecta. Br J Anaesth 1984; 56:1443.</a></li><li><a class="nounderline abstract_t">Porsborg P, Astrup G, Bendixen D, et al. Osteogenesis imperfecta and malignant hyperthermia. Is there a relationship? Anaesthesia 1996; 51:863.</a></li><li><a class="nounderline abstract_t">Bojanić K, Kivela JE, Gurrieri C, et al. Perioperative course and intraoperative temperatures in patients with osteogenesis imperfecta. Eur J Anaesthesiol 2011; 28:370.</a></li><li class="breakAll">http://www.mhaus.org/healthcare-professionals/mhaus-recommendations/does-noonan-syndrome-increase-malignant-hyperthermia-susceptibility (Accessed on September 29, 2014).</li><li><a class="nounderline abstract_t">Martin S, Tobias JD. Perioperative care of the child with arthrogryposis. Paediatr Anaesth 2006; 16:31.</a></li><li><a class="nounderline abstract_t">Baines DB, Douglas ID, Overton JH. Anaesthesia for patients with arthrogryposis multiplex congenita: what is the risk of malignant hyperthermia? Anaesth Intensive Care 1986; 14:370.</a></li><li><a class="nounderline abstract_t">Hopkins PM, Ellis FR, Halsall PJ. Hypermetabolism in arthrogryposis multiplex congenita. Anaesthesia 1991; 46:374.</a></li><li><a class="nounderline abstract_t">Parness J, Bandschapp O, Girard T. The myotonias and susceptibility to malignant hyperthermia. Anesth Analg 2009; 109:1054.</a></li><li><a class="nounderline abstract_t">Buzello W, Krieg N, Schlickewei A. Hazards of neostigmine in patients with neuromuscular disorders. Report of two cases. Br J Anaesth 1982; 54:529.</a></li><li><a class="nounderline abstract_t">Sangkuhl K, Dirksen RT, Alvarellos ML, et al. PharmGKB summary: very important pharmacogene information for CACNA1S. Pharmacogenet Genomics 2020; 30:34.</a></li><li><a class="nounderline abstract_t">Smego RA Jr, Durack DT. The neuroleptic malignant syndrome. Arch Intern Med 1982; 142:1183.</a></li><li><a class="nounderline abstract_t">Caroff SN, Rosenberg H, Fletcher JE, et al. Malignant hyperthermia susceptibility in neuroleptic malignant syndrome. Anesthesiology 1987; 67:20.</a></li><li><a class="nounderline abstract_t">Ward A, Chaffman MO, Sorkin EM. Dantrolene. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in malignant hyperthermia, the neuroleptic malignant syndrome and an update of its use in muscle spasticity. Drugs 1986; 32:130.</a></li><li><a class="nounderline abstract_t">Bello N, Adnet P, Saulnier F, et al. [Lack of sensitivity to per-anesthetic malignant hyperthermia in 32 patients who developed neuroleptic malignant syndrome]. Ann Fr Anesth Reanim 1994; 13:663.</a></li><li><a class="nounderline abstract_t">Larach MG, Gronert GA, Allen GC, et al. Clinical presentation, treatment, and complications of malignant hyperthermia in North America from 1987 to 2006. Anesth Analg 2010; 110:498.</a></li><li><a class="nounderline abstract_t">Bendixen D, Skovgaard LT, Ording H. Analysis of anaesthesia in patients suspected to be susceptible to malignant hyperthermia before diagnostic in vitro contracture test. Acta Anaesthesiol Scand 1997; 41:480.</a></li><li><a class="nounderline abstract_t">Strazis KP, Fox AW. Malignant hyperthermia: a review of published cases. Anesth Analg 1993; 77:297.</a></li><li><a class="nounderline abstract_t">Larach MG, Localio AR, Allen GC, et al. A clinical grading scale to predict malignant hyperthermia susceptibility. Anesthesiology 1994; 80:771.</a></li><li><a class="nounderline abstract_t">Gronert GA, Thompson RL, Onofrio BM. Human malignant hyperthermia: awake episodes and correction by dantrolene. Anesth Analg 1980; 59:377.</a></li><li><a class="nounderline abstract_t">Puerto N, Aoyama K, Der T, et al. Awake malignant hyperthermia: report of a case to help prevent crises in operating rooms. Can J Anaesth 2023; 70:169.</a></li><li><a class="nounderline abstract_t">Cummings T, Der T, Karsli C. Repeated nonanesthetic malignant hyperthermia reactions in a child. Paediatr Anaesth 2016; 26:1202.</a></li><li><a class="nounderline abstract_t">Litman RS, Rosenberg H. Malignant hyperthermia: update on susceptibility testing. JAMA 2005; 293:2918.</a></li><li><a class="nounderline abstract_t">Rosenberg H, Antognini JF, Muldoon S. Testing for malignant hyperthermia. Anesthesiology 2002; 96:232.</a></li><li><a class="nounderline abstract_t">Hopkins PM, Hartung E, Wappler F. Multicentre evaluation of ryanodine contracture testing in malignant hyperthermia. The European Malignant Hyperthermia Group. Br J Anaesth 1998; 80:389.</a></li><li><a class="nounderline abstract_t">Miller DM, Daly C, Aboelsaod EM, et al. Genetic epidemiology of malignant hyperthermia in the UK. Br J Anaesth 2018; 121:944.</a></li><li><a class="nounderline abstract_t">Allen GC, Larach MG, Kunselman AR. The sensitivity and specificity of the caffeine-halothane contracture test: a report from the North American Malignant Hyperthermia Registry. The North American Malignant Hyperthermia Registry of MHAUS. Anesthesiology 1998; 88:579.</a></li><li><a class="nounderline abstract_t">Ording H, Brancadoro V, Cozzolino S, et al. In vitro contracture test for diagnosis of malignant hyperthermia following the protocol of the European MH Group: results of testing patients surviving fulminant MH and unrelated low-risk subjects. The European Malignant Hyperthermia Group. Acta Anaesthesiol Scand 1997; 41:955.</a></li><li><a class="nounderline abstract_t">Mitchell LW, Leighton BL. Warmed diluent speeds dantrolene reconstitution. Can J Anaesth 2003; 50:127.</a></li><li><a class="nounderline abstract_t">Ellis FR, Harriman DG, Keaney NP, et al. Halothane-induced muscle contracture as a cause of hyperpyrexia. Br J Anaesth 1971; 43:721.</a></li><li><a class="nounderline abstract_t">A protocol for the investigation of malignant hyperpyrexia (MH) susceptibility. The European Malignant Hyperpyrexia Group. Br J Anaesth 1984; 56:1267.</a></li><li><a class="nounderline abstract_t">Fortunato G, Carsana A, Tinto N, et al. A case of discordance between genotype and phenotype in a malignant hyperthermia family. Eur J Hum Genet 1999; 7:415.</a></li><li><a class="nounderline abstract_t">Robinson RL, Curran JL, Ellis FR, et al. Multiple interacting gene products may influence susceptibility to malignant hyperthermia. Ann Hum Genet 2000; 64:307.</a></li><li><a class="nounderline abstract_t">Fiszer D, Shaw MA, Fisher NA, et al. Next-generation Sequencing of RYR1 and CACNA1S in Malignant Hyperthermia and Exertional Heat Illness. Anesthesiology 2015; 122:1033.</a></li><li><a class="nounderline abstract_t">Brandom BW, Bina S, Wong CA, et al. Ryanodine receptor type 1 gene variants in the malignant hyperthermia-susceptible population of the United States. Anesth Analg 2013; 116:1078.</a></li><li><a class="nounderline abstract_t">Girard T, Treves S, Voronkov E, et al. Molecular genetic testing for malignant hyperthermia susceptibility. Anesthesiology 2004; 100:1076.</a></li><li><a class="nounderline abstract_t">Timmins MA, Rosenberg H, Larach MG, et al. Malignant hyperthermia testing in probands without adverse anesthetic reaction. Anesthesiology 2015; 123:548.</a></li><li><a class="nounderline abstract_t">Runnstrom M, Ebied AM, Khoury AP, Reddy R. Influenza-induced rhabdomyolysis. BMJ Case Rep 2018; 11.</a></li><li><a class="nounderline abstract_t">Birgenheier N, Stoker R, Westenskow D, Orr J. Activated charcoal effectively removes inhaled anesthetics from modern anesthesia machines. Anesth Analg 2011; 112:1363.</a></li><li class="breakAll">https://www.mhaus.org/healthcare-professionals/mhaus-recommendations/preparation-of-anesthesia-workstations-to-anesthetize-mh-susceptible-patients/.</li><li class="breakAll">http://www.mhaus.org/healthcare-professionals/be-prepared/preparing-the-anesthesia-machine (Accessed on April 15, 2013).</li><li><a class="nounderline abstract_t">Petroz GC, Lerman J. Preparation of the Siemens KION anesthetic machine for patients susceptible to malignant hyperthermia. Anesthesiology 2002; 96:941.</a></li><li><a class="nounderline abstract_t">Prinzhausen H, Crawford MW, O'Rourke J, Petroz GC. Preparation of the Dräger Primus anesthetic machine for malignant hyperthermia-susceptible patients. Can J Anaesth 2006; 53:885.</a></li><li><a class="nounderline abstract_t">Kim TW, Nemergut ME. Preparation of modern anesthesia workstations for malignant hyperthermia-susceptible patients: a review of past and present practice. Anesthesiology 2011; 114:205.</a></li><li><a class="nounderline abstract_t">Jones PM, Allen BN, Cherry RA, et al. Association between known or strongly suspected malignant hyperthermia susceptibility and postoperative outcomes: an observational population-based study. Can J Anaesth 2019; 66:161.</a></li><li class="breakAll">http://www.mhaus.org/healthcare-professionals/be-prepared/post-operative-procedure (Accessed on April 15, 2013).</li><li><a class="nounderline abstract_t">Pollock N, Langtont E, Stowell K, et al. Safe duration of postoperative monitoring for malignant hyperthermia susceptible patients. Anaesth Intensive Care 2004; 32:502.</a></li><li><a class="nounderline abstract_t">Barnes C, Stowell KM, Bulger T, et al. Safe duration of postoperative monitoring for malignant hyperthermia patients administered non-triggering anaesthesia: an update. Anaesth Intensive Care 2015; 43:98.</a></li><li class="breakAll">http://www.mhaus.org/healthcare-professionals/mhaus-recommendations/parturient-with-mhs-partner (Accessed on April 16, 2013).</li></ol></div><div id="topicVersionRevision">Topic 403 Version 52.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9798607" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Malignant hyperthermia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8332154" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Hyperthermia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19762722" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Malignant hyperthermia-associated diseases: state of the art uncertainty.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11553240" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Malignant hyperthermia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1589759" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Malignant hyperthermia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8789133" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Disorders of temperature regulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18362591" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Cardiac arrests and deaths associated with malignant hyperthermia in north america from 1987 to 2006: a report from the north american malignant hyperthermia registry of the malignant hyperthermia association of the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19104175" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Trends and outcomes of malignant hyperthermia in the United States, 2000 to 2005.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25268394" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Malignant hyperthermia deaths related to inadequate temperature monitoring, 2007-2012: a report from the North American malignant hyperthermia registry of the malignant hyperthermia association of the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12411788" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Presence of two different genetic traits in malignant hyperthermia families: implication for genetic analysis, diagnosis, and incidence of malignant hyperthermia susceptibility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12411788" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Presence of two different genetic traits in malignant hyperthermia families: implication for genetic analysis, diagnosis, and incidence of malignant hyperthermia susceptibility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24433488" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Functional and genetic characterization of clinical malignant hyperthermia crises: a multi-centre study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31206373" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : An Assessment of Penetrance and Clinical Expression of Malignant Hyperthermia in Individuals Carrying Diagnostic Ryanodine Receptor 1 Gene Mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19762721" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : The association of malignant hyperthermia and unusual disease: when you're hot you're hot or maybe not.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30499100" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for the Use of Potent Volatile Anesthetic Agents and Succinylcholine in the Context of RYR1 or CACNA1S Genotypes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32898259" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Genomic Screening for Malignant Hyperthermia Susceptibility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18553514" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Native American myopathy: congenital myopathy with cleft palate, skeletal anomalies, and susceptibility to malignant hyperthermia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : STAC3 p.Trp284Ser associated with congenital myopathy with distinctive dysmorphic features and malignant hyperthermia</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18843099" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Novel congenital myopathy locus identified in Native American Indians at 12q13.13-14.1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3631569" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Malignant hyperthermia in a three-month-old American Indian infant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35697689" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Variants in ASPH cause exertional heat illness and are associated with malignant hyperthermia susceptibility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19648156" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Genetic variation in RYR1 and malignant hyperthermia phenotypes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12700608" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Recent advances in the diagnosis of malignant hyperthermia susceptibility: how confident can we be of genetic testing?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15731587" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Screening of the entire ryanodine receptor type 1 coding region for sequence variants associated with malignant hyperthermia susceptibility in the north american population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15731587" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Screening of the entire ryanodine receptor type 1 coding region for sequence variants associated with malignant hyperthermia susceptibility in the north american population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11260227" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Identification of the Arg1086His mutation in the alpha subunit of the voltage-dependent calcium channel (CACNA1S) in a North American family with malignant hyperthermia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1967823" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Ryanodine receptor gene is a candidate for predisposition to malignant hyperthermia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2300206" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Localization of the malignant hyperthermia susceptibility locus to human chromosome 19q12-13.2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12732639" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Functional defects in six ryanodine receptor isoform-1 (RyR1) mutations associated with malignant hyperthermia and their impact on skeletal excitation-contraction coupling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19346234" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Mutation screening of the RYR1-cDNA from peripheral B-lymphocytes in 15 Swedish malignant hyperthermia index cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10484775" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Screening of the ryanodine receptor gene in 105 malignant hyperthermia families: novel mutations and concordance with the in vitro contracture test.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11668625" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Genotype-phenotype comparison of the Swiss malignant hyperthermia population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9199552" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Malignant-hyperthermia susceptibility is associated with a mutation of the alpha 1-subunit of the human dihydropyridine-sensitive L-type voltage-dependent calcium-channel receptor in skeletal muscle.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12059893" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Mutation screening in the ryanodine receptor 1 gene (RYR1) in patients susceptible to malignant hyperthermia who show definite IVCT results: identification of three novel mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15448513" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Malignant hyperthermia in North America: genetic screening of the three hot spots in the type I ryanodine receptor gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30325262" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : RYR1 and CACNA1S genetic variants identified with statin-associated muscle symptoms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8220423" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Mutations in the ryanodine receptor gene in central core disease and malignant hyperthermia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12467748" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : The spectrum of pathology in central core disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19762745" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Core myopathies and risk of malignant hyperthermia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8220422" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : A mutation in the human ryanodine receptor gene associated with central core disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14732627" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Multiminicore disease in a family susceptible to malignant hyperthermia: histology, in vitro contracture tests, and genetic characterization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18765655" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : King-denborough syndrome caused by a novel mutation in the ryanodine receptor gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11448278" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Malignant hyperthermia and apparent heat stroke.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8186710" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Pathological findings in 165 patients explored for malignant hyperthermia susceptibility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11524341" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : A noninvasive investigation of muscle energetics supports similarities between exertional heat stroke and malignant hyperthermia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9051549" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Sudden unexplained death in a patient with a family history of malignant hyperthermia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9619231" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Rhabdomyolysis following severe physical exercise in a patient with predisposition to malignant hyperthermia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11135728" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Evidence for susceptibility to malignant hyperthermia in patients with exercise-induced rhabdomyolysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19807743" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : The ryanodine receptor type 1 gene variants in African American men with exertional rhabdomyolysis and malignant hyperthermia susceptibility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28326467" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Malignant hyperthermia susceptibility in patients with exertional rhabdomyolysis: a retrospective cohort study and updated systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30805902" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Fatal awake malignant hyperthermia episodes in a family with malignant hyperthermia susceptibility: a case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23267001" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Case report: Death in the emergency department: an unrecognized awake malignant hyperthermia-like reaction in a six-year-old.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25611019" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Improving awareness of nonanesthesia-related malignant hyperthermia presentations: a tale of two brothers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21918424" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Identical de novo mutation in the type 1 ryanodine receptor gene associated with fatal, stress-induced malignant hyperthermia in two unrelated families.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25081049" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Fever-induced recurrent rhabdomyolysis due to a novel mutation in the ryanodine receptor type 1 gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32054689" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Investigating the genetic susceptibility to exertional heat illness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21795085" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Genetic risk for malignant hyperthermia in non-anesthesia-induced myopathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15318472" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Malignant hyperthermia susceptibility revealed by increased serum creatine kinase concentrations during statin treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12687516" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Rhabdomyolysis and myalgia associated with anticholesterolemic treatment as potential signs of malignant hyperthermia susceptibility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19762730" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Malignant hyperthermia and muscular dystrophies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19762731" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Malignant hyperthermia, coexisting disorders, and enzymopathies: risks and management options.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12459698" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Positive malignant hyperthermia susceptibility in vitro test in a patient with mitochondrial myopathy and myoadenylate deaminase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2498654" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Myophosphorylase B deficiency and malignant hyperthermia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10422956" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Noncardiogenic pulmonary edema and rhabdomyolsis after protamine administration in a patient with unrecognized McArdle's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16095447" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : McArdle's disease and anaesthesia: case reports. Review of potential problems and association with malignant hyperthermia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3256299" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Postanesthetic acute renal failure due to carnitine palmityl transferase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19762733" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Malignant hyperthermia-like syndrome and carnitine palmitoyltransferase II deficiency with heterozygous R503C mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32040565" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Clinical, morphological and genetic characterization of Brody disease: an international study of 40 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2735548" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Osteogenesis imperfecta and hyperthermia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6498054" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Occurrence of malignant hyperpyrexia in a patient with osteogenesis imperfecta.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8882252" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Osteogenesis imperfecta and malignant hyperthermia. Is there a relationship?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21423018" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Perioperative course and intraoperative temperatures in patients with osteogenesis imperfecta.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21423018" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Perioperative course and intraoperative temperatures in patients with osteogenesis imperfecta.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16409526" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Perioperative care of the child with arthrogryposis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3565726" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Anaesthesia for patients with arthrogryposis multiplex congenita: what is the risk of malignant hyperthermia?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2035784" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Hypermetabolism in arthrogryposis multiplex congenita.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19762732" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : The myotonias and susceptibility to malignant hyperthermia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7073921" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Hazards of neostigmine in patients with neuromuscular disorders. Report of two cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31851124" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : PharmGKB summary: very important pharmacogene information for CACNA1S.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6124221" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : The neuroleptic malignant syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3605730" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Malignant hyperthermia susceptibility in neuroleptic malignant syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3527659" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Dantrolene. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in malignant hyperthermia, the neuroleptic malignant syndrome and an update of its use in muscle spasticity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7733515" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : [Lack of sensitivity to per-anesthetic malignant hyperthermia in 32 patients who developed neuroleptic malignant syndrome].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20081135" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Clinical presentation, treatment, and complications of malignant hyperthermia in North America from 1987 to 2006.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9150775" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Analysis of anaesthesia in patients suspected to be susceptible to malignant hyperthermia before diagnostic in vitro contracture test.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8346828" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Malignant hyperthermia: a review of published cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8024130" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : A clinical grading scale to predict malignant hyperthermia susceptibility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7189384" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Human malignant hyperthermia: awake episodes and correction by dantrolene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36369638" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Awake malignant hyperthermia: report of a case to help prevent crises in operating rooms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27562486" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Repeated nonanesthetic malignant hyperthermia reactions in a child.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15956637" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Malignant hyperthermia: update on susceptibility testing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11753023" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Testing for malignant hyperthermia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9623444" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Multicentre evaluation of ryanodine contracture testing in malignant hyperthermia. The European Malignant Hyperthermia Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30236257" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Genetic epidemiology of malignant hyperthermia in the UK.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9523799" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : The sensitivity and specificity of the caffeine-halothane contracture test: a report from the North American Malignant Hyperthermia Registry. The North American Malignant Hyperthermia Registry of MHAUS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9311391" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : In vitro contracture test for diagnosis of malignant hyperthermia following the protocol of the European MH Group: results of testing patients surviving fulminant MH and unrelated low-risk subjects. The European Malignant Hyperthermia Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12560301" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Warmed diluent speeds dantrolene reconstitution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5564247" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Halothane-induced muscle contracture as a cause of hyperpyrexia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6487446" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : A protocol for the investigation of malignant hyperpyrexia (MH) susceptibility. The European Malignant Hyperpyrexia Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10352931" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : A case of discordance between genotype and phenotype in a malignant hyperthermia family.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11415515" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Multiple interacting gene products may influence susceptibility to malignant hyperthermia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25658027" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Next-generation Sequencing of RYR1 and CACNA1S in Malignant Hyperthermia and Exertional Heat Illness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23558838" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Ryanodine receptor type 1 gene variants in the malignant hyperthermia-susceptible population of the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15114203" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Molecular genetic testing for malignant hyperthermia susceptibility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26068069" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Malignant hyperthermia testing in probands without adverse anesthetic reaction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30567189" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Influenza-induced rhabdomyolysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21543783" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Activated charcoal effectively removes inhaled anesthetics from modern anesthesia machines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21543783" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Activated charcoal effectively removes inhaled anesthetics from modern anesthesia machines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21543783" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Activated charcoal effectively removes inhaled anesthetics from modern anesthesia machines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11964603" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Preparation of the Siemens KION anesthetic machine for patients susceptible to malignant hyperthermia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16960266" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Preparation of the Dräger Primus anesthetic machine for malignant hyperthermia-susceptible patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21169802" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Preparation of modern anesthesia workstations for malignant hyperthermia-susceptible patients: a review of past and present practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30421146" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Association between known or strongly suspected malignant hyperthermia susceptibility and postoperative outcomes: an observational population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30421146" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Association between known or strongly suspected malignant hyperthermia susceptibility and postoperative outcomes: an observational population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15675210" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Safe duration of postoperative monitoring for malignant hyperthermia susceptible patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25579296" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Safe duration of postoperative monitoring for malignant hyperthermia patients administered non-triggering anaesthesia: an update.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
